Novartis AG – Consensus Indicates Potential 22.5% Upside Novartis AG with ticker code (NVS) now have 5 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 108 and 97 with the average target price sitting at 103.2. With the stocks previous close at 84.22 this is indicating there is a potential upside of 22.5%. There is a 50 day moving average of 85.76 and the 200 day MA is 85.68. The company has a market cap of $189,013m. Find out more information at: https:||www.novartis.com [stock_market_widget type="chart" template="basic" color="green" assets="NVS" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $231,609m based on the market concensus. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.